BIOplasma | Use flexible Tube Micro Plasma (FµTP) for Lipidomics

Summary
Cancer is the leading cause of death in economically developed countries and the second leading cause of death in developing countries. In 2015, over 8.8 million people died of cancer worldwide and the numbers are expected to rise above 13 million in 2030 . As a consequence, development of non-invasive, fast and robust methods to detect different types of cancer in an early stage are timely. BIOplasma addresses the essential need for analytical tools that permit the diagnosis of biological tissues. A novel analytical strategy based on the Liquid Chromatography/Mass Spectrometry (LC-MS) using flexible Tube Micro Plasma (FµTP) as ionization source for the identification and quantification of several lipid biomarkers in body fluids is proposed
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/840743
Start date: 01-05-2019
End date: 30-04-2021
Total budget - Public funding: 162 806,40 Euro - 162 806,00 Euro
Cordis data

Original description

Cancer is the leading cause of death in economically developed countries and the second leading cause of death in developing countries. In 2015, over 8.8 million people died of cancer worldwide and the numbers are expected to rise above 13 million in 2030 . As a consequence, development of non-invasive, fast and robust methods to detect different types of cancer in an early stage are timely. BIOplasma addresses the essential need for analytical tools that permit the diagnosis of biological tissues. A novel analytical strategy based on the Liquid Chromatography/Mass Spectrometry (LC-MS) using flexible Tube Micro Plasma (FµTP) as ionization source for the identification and quantification of several lipid biomarkers in body fluids is proposed

Status

TERMINATED

Call topic

MSCA-IF-2018

Update Date

28-04-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.1. EXCELLENT SCIENCE
H2020-EU.1.3. EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions (MSCA)
H2020-EU.1.3.2. Nurturing excellence by means of cross-border and cross-sector mobility
H2020-MSCA-IF-2018
MSCA-IF-2018